ANI Pharmaceuticals (ANIP) Competitors

$77.87 -1.71 (-2.15%)

As of 01:56 PM Eastern

ANIP vs. ADMA, ANVS, QGEN, ACLX, and KYMR

Should you buy ANI Pharmaceuticals stock or one of its competitors? MarketBeat compares ANI Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ANI Pharmaceuticals include ADMA Biologics (ADMA), Annovis Bio (ANVS), Qiagen (QGEN), Arcellx (ACLX), and Kymera Therapeutics (KYMR). These companies are all part of the "pharmaceutical products" industry.

How does ANI Pharmaceuticals compare to ADMA Biologics?

ANI Pharmaceuticals (NASDAQ:ANIP) and ADMA Biologics (NASDAQ:ADMA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability and dividends.

ANI Pharmaceuticals has a beta of 0.46, suggesting that its share price is 54% less volatile than the broader market. Comparatively, ADMA Biologics has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market.

In the previous week, ANI Pharmaceuticals had 4 more articles in the media than ADMA Biologics. MarketBeat recorded 20 mentions for ANI Pharmaceuticals and 16 mentions for ADMA Biologics. ANI Pharmaceuticals' average media sentiment score of 0.36 beat ADMA Biologics' score of 0.34 indicating that ANI Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ANI Pharmaceuticals	6 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ADMA Biologics	2 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

76.1% of ANI Pharmaceuticals shares are held by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are held by institutional investors. 8.1% of ANI Pharmaceuticals shares are held by insiders. Comparatively, 3.9% of ADMA Biologics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

ADMA Biologics has a net margin of 32.43% compared to ANI Pharmaceuticals' net margin of 9.98%. ADMA Biologics' return on equity of 39.98% beat ANI Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	9.98%	27.51%	10.02%
ADMA Biologics	32.43%	39.98%	28.08%

ANI Pharmaceuticals presently has a consensus price target of $107.33, suggesting a potential upside of 37.84%. ADMA Biologics has a consensus price target of $19.00, suggesting a potential upside of 128.78%. Given ADMA Biologics' higher probable upside, analysts plainly believe ADMA Biologics is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.88
ADMA Biologics	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40

ADMA Biologics has lower revenue, but higher earnings than ANI Pharmaceuticals. ADMA Biologics is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$883.37M	1.98	$78.34M	$3.95	19.71
ADMA Biologics	$510.17M	3.77	$146.93M	$0.68	12.21

Summary

ANI Pharmaceuticals beats ADMA Biologics on 10 of the 17 factors compared between the two stocks.

How does ANI Pharmaceuticals compare to Annovis Bio?

Annovis Bio (NYSE:ANVS) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.

Annovis Bio has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market. Comparatively, ANI Pharmaceuticals has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market.

ANI Pharmaceuticals has a net margin of 9.98% compared to Annovis Bio's net margin of 0.00%. ANI Pharmaceuticals' return on equity of 27.51% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annovis Bio	N/A	-159.43%	-133.49%
ANI Pharmaceuticals	9.98%	27.51%	10.02%

Annovis Bio currently has a consensus price target of $13.50, suggesting a potential upside of 558.86%. ANI Pharmaceuticals has a consensus price target of $107.33, suggesting a potential upside of 37.84%. Given Annovis Bio's higher possible upside, research analysts clearly believe Annovis Bio is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
ANI Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.88

ANI Pharmaceuticals has higher revenue and earnings than Annovis Bio. Annovis Bio is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annovis Bio	N/A	N/A	-$28.85M	-$1.40	N/A
ANI Pharmaceuticals	$883.37M	1.98	$78.34M	$3.95	19.71

15.8% of Annovis Bio shares are owned by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are owned by institutional investors. 20.8% of Annovis Bio shares are owned by company insiders. Comparatively, 8.1% of ANI Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, ANI Pharmaceuticals had 18 more articles in the media than Annovis Bio. MarketBeat recorded 20 mentions for ANI Pharmaceuticals and 2 mentions for Annovis Bio. ANI Pharmaceuticals' average media sentiment score of 0.36 beat Annovis Bio's score of 0.00 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annovis Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ANI Pharmaceuticals	6 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

ANI Pharmaceuticals beats Annovis Bio on 13 of the 16 factors compared between the two stocks.

How does ANI Pharmaceuticals compare to Qiagen?

Qiagen (NYSE:QGEN) and ANI Pharmaceuticals (NASDAQ:ANIP) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.

Qiagen has a beta of 0.64, suggesting that its stock price is 36% less volatile than the broader market. Comparatively, ANI Pharmaceuticals has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market.

Qiagen has a net margin of 19.16% compared to ANI Pharmaceuticals' net margin of 9.98%. ANI Pharmaceuticals' return on equity of 27.51% beat Qiagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.16%	14.40%	8.40%
ANI Pharmaceuticals	9.98%	27.51%	10.02%

Qiagen currently has a consensus price target of $46.38, suggesting a potential upside of 40.35%. ANI Pharmaceuticals has a consensus price target of $107.33, suggesting a potential upside of 37.84%. Given Qiagen's higher possible upside, research analysts clearly believe Qiagen is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	0 Sell rating(s)	7 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50
ANI Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.88

Qiagen has higher revenue and earnings than ANI Pharmaceuticals. Qiagen is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.09B	3.26	$424.88M	$1.91	17.30
ANI Pharmaceuticals	$883.37M	1.98	$78.34M	$3.95	19.71

70.0% of Qiagen shares are owned by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are owned by institutional investors. 9.0% of Qiagen shares are owned by company insiders. Comparatively, 8.1% of ANI Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, ANI Pharmaceuticals had 5 more articles in the media than Qiagen. MarketBeat recorded 20 mentions for ANI Pharmaceuticals and 15 mentions for Qiagen. ANI Pharmaceuticals' average media sentiment score of 0.36 beat Qiagen's score of 0.29 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	1 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
ANI Pharmaceuticals	6 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

ANI Pharmaceuticals beats Qiagen on 9 of the 16 factors compared between the two stocks.

How does ANI Pharmaceuticals compare to Arcellx?

ANI Pharmaceuticals (NASDAQ:ANIP) and Arcellx (NASDAQ:ACLX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations.

In the previous week, ANI Pharmaceuticals had 20 more articles in the media than Arcellx. MarketBeat recorded 20 mentions for ANI Pharmaceuticals and 0 mentions for Arcellx. Arcellx's average media sentiment score of 1.07 beat ANI Pharmaceuticals' score of 0.36 indicating that Arcellx is being referred to more favorably in the news media.

Company	Overall Sentiment
ANI Pharmaceuticals	Neutral
Arcellx	Positive

ANI Pharmaceuticals has higher revenue and earnings than Arcellx. Arcellx is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$883.37M	1.98	$78.34M	$3.95	19.71
Arcellx	$22.29M	301.95	-$228.93M	-$4.07	N/A

ANI Pharmaceuticals has a beta of 0.46, indicating that its stock price is 54% less volatile than the broader market. Comparatively, Arcellx has a beta of 0.25, indicating that its stock price is 75% less volatile than the broader market.

76.1% of ANI Pharmaceuticals shares are owned by institutional investors. Comparatively, 96.0% of Arcellx shares are owned by institutional investors. 8.1% of ANI Pharmaceuticals shares are owned by insiders. Comparatively, 8.4% of Arcellx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

ANI Pharmaceuticals has a net margin of 9.98% compared to Arcellx's net margin of -1,027.26%. ANI Pharmaceuticals' return on equity of 27.51% beat Arcellx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	9.98%	27.51%	10.02%
Arcellx	-1,027.26%	-55.42%	-36.24%

ANI Pharmaceuticals presently has a consensus price target of $107.33, indicating a potential upside of 37.84%. Arcellx has a consensus price target of $111.87, indicating a potential downside of 2.78%. Given ANI Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe ANI Pharmaceuticals is more favorable than Arcellx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.88
Arcellx	1 Sell rating(s)	16 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.11

Summary

ANI Pharmaceuticals beats Arcellx on 12 of the 16 factors compared between the two stocks.

How does ANI Pharmaceuticals compare to Kymera Therapeutics?

ANI Pharmaceuticals (NASDAQ:ANIP) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations.

In the previous week, ANI Pharmaceuticals had 10 more articles in the media than Kymera Therapeutics. MarketBeat recorded 20 mentions for ANI Pharmaceuticals and 10 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.42 beat ANI Pharmaceuticals' score of 0.36 indicating that Kymera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ANI Pharmaceuticals	6 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kymera Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ANI Pharmaceuticals has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$883.37M	1.98	$78.34M	$3.95	19.71
Kymera Therapeutics	$39.21M	172.01	-$311.35M	-$3.57	N/A

ANI Pharmaceuticals has a beta of 0.46, indicating that its stock price is 54% less volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 2.06, indicating that its stock price is 106% more volatile than the broader market.

76.1% of ANI Pharmaceuticals shares are owned by institutional investors. 8.1% of ANI Pharmaceuticals shares are owned by insiders. Comparatively, 16.0% of Kymera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

ANI Pharmaceuticals has a net margin of 9.98% compared to Kymera Therapeutics' net margin of -611.94%. ANI Pharmaceuticals' return on equity of 27.51% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	9.98%	27.51%	10.02%
Kymera Therapeutics	-611.94%	-24.71%	-22.05%

ANI Pharmaceuticals presently has a consensus price target of $107.33, indicating a potential upside of 37.84%. Kymera Therapeutics has a consensus price target of $118.10, indicating a potential upside of 44.04%. Given Kymera Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Kymera Therapeutics is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.88
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.96

Summary

ANI Pharmaceuticals beats Kymera Therapeutics on 9 of the 16 factors compared between the two stocks.

Get ANI Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANIP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANIP vs. The Competition

Export

Metric	ANI Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.75B	$3.33B	$6.24B	$12.30B
Dividend Yield	N/A	2.31%	2.80%	5.35%
P/E Ratio	19.71	18.15	20.39	25.31
Price / Sales	1.98	280.54	541.96	72.69
Price / Cash	8.14	125.29	43.26	56.33
Price / Book	3.10	6.67	9.79	6.90
Net Income	$78.34M	$24.11M	$3.56B	$333.98M
7 Day Performance	-4.87%	3.81%	0.43%	-0.27%
1 Month Performance	1.82%	-3.19%	-0.87%	1.56%
1 Year Performance	30.81%	68.06%	35.95%	32.45%

ANI Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANIP ANI Pharmaceuticals	3.7704 of 5 stars	$77.87 -2.1%	$107.33 +37.8%	+31.8%	$1.75B	$883.37M	19.71	600	Earnings Report Insider Trade
ADMA ADMA Biologics	4.6512 of 5 stars	$10.31 -2.0%	$25.67 +148.9%	-56.3%	$2.51B	$510.17M	17.18	530	Insider Trade
ANVS Annovis Bio	1.9838 of 5 stars	$2.28 +13.9%	$13.50 +492.6%	+25.2%	$58.54M	N/A	N/A	3	News Coverage Earnings Report Upcoming Earnings
QGEN Qiagen	4.5662 of 5 stars	$33.90 -1.0%	$47.09 +38.9%	-23.3%	$7.06B	$2.09B	16.81	5,654	Dividend Increase Analyst Downgrade
ACLX Arcellx	2.4781 of 5 stars	$115.07 flat	$111.87 -2.8%	+95.0%	$6.73B	$22.29M	N/A	80	Positive News High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANIP) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ANI Pharmaceuticals (ANIP) Competitors

ANIP vs. ADMA, ANVS, QGEN, ACLX, and KYMR

How does ANI Pharmaceuticals compare to ADMA Biologics?

Summary

How does ANI Pharmaceuticals compare to Annovis Bio?

Summary

How does ANI Pharmaceuticals compare to Qiagen?

Summary

How does ANI Pharmaceuticals compare to Arcellx?

Summary

How does ANI Pharmaceuticals compare to Kymera Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIP vs. The Competition

ANI Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ANI Pharmaceuticals (ANIP) Competitors

ANIP vs. ADMA, ANVS, QGEN, ACLX, and KYMR

How does ANI Pharmaceuticals compare to ADMA Biologics?

Which has more volatility & risk, ANIP or ADMA?

Does the media prefer ANIP or ADMA?

Do institutionals & insiders hold more shares of ANIP or ADMA?

Is ANIP or ADMA more profitable?

Do analysts rate ANIP or ADMA?

Which has stronger valuation & earnings, ANIP or ADMA?

Summary

How does ANI Pharmaceuticals compare to Annovis Bio?

Which has more volatility & risk, ANVS or ANIP?

Is ANVS or ANIP more profitable?

Do analysts rate ANVS or ANIP?

Which has higher earnings & valuation, ANVS or ANIP?

Do institutionals and insiders hold more shares of ANVS or ANIP?

Does the media favor ANVS or ANIP?

Summary

How does ANI Pharmaceuticals compare to Qiagen?

Which has more volatility & risk, QGEN or ANIP?

Is QGEN or ANIP more profitable?

Do analysts rate QGEN or ANIP?

Which has higher earnings & valuation, QGEN or ANIP?

Do institutionals and insiders hold more shares of QGEN or ANIP?

Does the media favor QGEN or ANIP?

Summary

How does ANI Pharmaceuticals compare to Arcellx?

Does the media prefer ANIP or ACLX?

Which has higher valuation and earnings, ANIP or ACLX?

Which has more volatility and risk, ANIP or ACLX?

Do insiders & institutionals believe in ANIP or ACLX?

Is ANIP or ACLX more profitable?

Do analysts rate ANIP or ACLX?

Summary

How does ANI Pharmaceuticals compare to Kymera Therapeutics?

Does the media prefer ANIP or KYMR?

Which has higher valuation and earnings, ANIP or KYMR?

Which has more volatility and risk, ANIP or KYMR?

Do insiders & institutionals believe in ANIP or KYMR?

Is ANIP or KYMR more profitable?

Do analysts rate ANIP or KYMR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIP vs. The Competition

ANI Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools